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Abstract
Background: About 20–30% of persons with HIV infection, especially those living in countries
with limited resources, experience an immune reconstitution inflammatory syndrome (IRIS) after
starting antiretroviral treatment. The active form of vitamin D, 1,25-dihydroxyvitamin D, is a key
player in the clearance of pathogens and influences the level of inflammation and macrophage
activation.
Presentation of the hypothesis: We hypothesize that low availability of 1,25-dihydroxyvitamin
D, either due to vitamin D deficiency or due to polymorphisms in the vitamin D receptor or in its
activating/inactivating enzymes, contributes to the appearance of IRIS. Furthermore, drug
interactions with the enzymatic pathways of vitamin D could favour the development of IRIS.
Testing the hypothesis: Our hypothesis could be explored by a case-control study to assess the
prevalence of vitamin D deficiency in HIV-infected patients on antiretroviral treatment who
develop and do not develop IRIS.
Implications of the hypothesis: If the role of vitamin D in IRIS is confirmed, we would be able
to screen patients at risk for IRIS by screening for vitamin D deficiency. After confirmation by
means of a clinical trial, vitamin D supplementation could be a cheap and safe way to reduce the
incidence of IRIS.
Background
Highly active anti-retroviral therapy (HAART) decreases
the mortality and improves the quality of life of persons
living with human immunodeficiency virus (HIV) infec-
tion [1]. Nevertheless, 17–32% of HIV infected persons
living in countries with limited resources experience a
temporary worsening of their clinical status after starting
HAART despite immunological improvement [2,3]. This
paradoxical reaction occurs most frequently during the
first 3 months after initiation of HAART and is known as
immune reconstitution inflammatory syndrome (IRIS) or
immune restoration disease (IRD) [4]. To date, more than
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20 different pathogens have been associated with IRIS
[2,3,5,6]. However, IRIS has also been described in associ-
ation with autoimmune diseases, cancer, and some non-
infectious granulomatous diseases such as sarcoidosis and
Crohn's disease [7].
In countries with limited resources, Mycobacteria sp. are
by far the most common pathogens involved [5].
There is now evidence that vitamin D plays a role in
improving anti-tuberculosis immunity as well as in the
regulation of immune responses [8-11], both of which are
crucial steps in the development of IRIS. A double blind
randomized controlled trial showed that a single dose of
vitamin D significantly enhanced immunity to Mycobacte-
ria tuberculosis (Mtb) among contacts of tuberculosis (TB)-
infected patients [12]. Liu et al showed later that vitamin
D acts by increasing the level of the antimicrobial peptide
cathelicidin produced by monocytes and macrophages
[13,14].
Low levels of vitamin D levels have been observed in Afri-
can populations [15] as well as in HIV-infected persons
(reviewed by Villamor [16]). A recent study in a cohort of
HIV-positive patients in the Netherlands (73% white,
20% black) showed a prevalence of vitamin D deficiency
of 29% in the total population, and 62% in black patients.
Low levels of active vitamin D have been associated with
low CD4 counts and AIDS progression [17].
TB treatment is also known to interfere with vitamin D
metabolism and to cause osteomalacia [18]. Vitamin D
deficiency may be influenced by deficient substrate, but
also by polymorphisms in its receptor or in the enzymes
controlling the activation of this steroid.
Presentation of the hypothesis
Low levels of vitamin D could predispose HIV infected
patients with a current or undiagnosed opportunistic
infection (OI) to IRIS. Indeed, the active form of vitamin
D, 1,25-(OH)2D, has anti-inflammatory activity [19] and
there is now accumulating evidence for its role in the reg-
ulation of human T-cell and antigen-presenting cell (APC)
functions [20,21]. Furthermore, drug interactions with
the enzymatic pathways of vitamin D [22] could favour
the development of IRIS.
Pathogenesis of IRIS
HIV causes progressive depletion of CD4+ T-cells and
impairs the immune system [2,5]. In HIV/Mtb patients
with severe immunodeficiency, impaired T-cell function
impedes granuloma formation [23]. When HAART is
started, T-cell function is restored and granuloma forma-
tion is re-established, mainly in the lungs and lymph
nodes, through activation of Mtb-infected macrophages
by interferon-γ (IFN-γ) producing T-cells [23]. Unfortu-
nately, rapid or unbalanced restoration of the immune
system against living or death organisms [7,24] may also
lead to uncontrolled antigen-specific responses [2] with
reappearance of clinical symptoms [5] and development
of IRIS.
Known risk factors for the development of IRIS include a
low CD4 T-cell count when starting HAART, advanced OI
with high OI antigen load, and a short time interval
between OI treatment and the start of HAART [2,25-28].
Other risk factors such as younger age, male gender, a
higher CD8 T-cell percentage, a high viral load at baseline,
a fast increase in CD4 T-cell count and fast decrease in
viral load after the start of HAART, and a protease inhibi-
tor (PI) based HAART regimen, were reported in some
studies but not in others [29].
Vitamin D and the immune system
The main source of vitamin D stems from sun exposure:
pre-vitamin D is converted by solar ultraviolet B radiation
in the skin into vitamin D. Skin pigmentation is a known
risk factor for hypovitaminosis D since melanin, responsi-
ble for the skin pigmentation, filters UV radiation [30-32].
Food uptake is limited to vitamin D supplementation or
consumption of oily fish [31]. Vitamin D is transported
into the blood by the vitamin D-binding protein (VDBP)
is converted in the liver by 25-hydroxylases (CYP34A,
CYP27A1, CYP2R1, ...) into 25-hydroxyvitamin D (25-
(OH)D). 25-(OH)D is considered the best indicator of
vitamin D status [31,33] with normal levels between 30
and 50 ng/ml [34]. Vitamin D deficiency is defined as 25-
(OH)D below 20 ng/ml [31]. The cytochrome CYP3A4,
present in liver, intestine, kidney and leukocytes [35] is
also a key enzyme in P450 cytochrome-mediated drug
metabolism such as anti-retrovirals (non nucleoside
reverse transcriptase inhibitor and PI) as well as certain
anti-tuberculous drugs (rifampicin and isoniazid)
[18,33,35]. The inactive form of vitamin D, 25-(OH)D, is
converted in kidney cells into its circulating active form
1,25-(OH)2D by the enzyme 1-α-hydroxylase (CYP27B1).
Other cells such as macrophages also express CYP27B1
[33]. In the late phase of macrophage activation, macro-
phage-CYP27B1 produces 1,25-(OH)2D which presuma-
bly has a local rather than a systemic effect on immune
cells [20]. Although the macrophage-CYP27B1 is identical
to the renal CYP27B1, its expression is not down-regu-
lated by the parathyroid hormone nor the active vitamin
D and is mainly up-regulated by inflammatory cytokines
such as IFN-γ and by lipopolysaccharides (LPS) [20,33].
Figure 1 illustrates the complex action of active vitamin D
on regulatory and effector T-cells and on APC, which
results in a negative feedback on macrophage activation to
prevent their overstimulation [20,36].AIDS Research and Therapy 2009, 6:4 http://www.aidsrestherapy.com/content/6/1/4
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To exert its actions, 1,25-(OH)2D binds to the vitamin D
receptor (VDR) expressed in normal, malignant and
immune cells [34]. At least 36 tissues possess VDR and
more than 10 tissues are able to produce 1,25-(OH)2D in
a paracrine fashion [8]. By the wide expression of VDR [8],
1,25-(OH)2D can regulate calcium homeostasis and bone
metabolism as well as play an essential role in cell prolif-
eration, differentiation and the above described regula-
tion of the immune response [31,33]. The variability in
patients' susceptibility to immune dysfunction and thus
IRIS could be explained by the polymorphisms of the
VDR gene known to influence immune cell function [37],
or by polymorphisms of hydroxylases regulating the pro-
duction or the degradation of the bioactive vitamin D.
Vitamin D, HAART and IRIS
During HAART and immune reconstitution, pathogen-
derived antigens are de novo recognized by APC, proc-
essed and presented to CD4+ T-cells leading to T-cell acti-
vation and secretion of macrophage-activating interferon-
γ. Vitamin D inhibits this IFN-γ production [34].
In case of low 25-(OH)D levels prior to HAART, we
hypothesize that a defective clearing of pathogens and a
delayed negative feedback on macrophage activation due
to low 1,25-(OH)2D production, can lead to excessive
granuloma formation and an exacerbated inflammatory
response described as IRIS.
To avoid macrophage-overstimulation, vitamin D should
be given before their massive activation, i.e. before the ini-
tiation of the inflammation. Indeed vitamin D decreases
immune stimulation [38], but if vitamin D is given when
granulomas are already flourishing, the 1α-hydroxylase in
activated macrophages can produce high amounts of
1,25-(OH)2D with systemic spillover [34] resulting in
hypercalcemia [38] as described in Mtb-IRIS [39-41] and
cryptococcus-IRIS [42]. At that moment vitamin D supple-
mentation could worsen the clinical status of the patient.
Protease inhibitors (PI) are known to interfere with vita-
min D metabolism (Figure 2) reducing 1,25-(OH)2D lev-
els [22]. Low 1,25-(OH)2D levels and bone loss has been
described to be most frequent in PI-treated patients com-
pared to other HAART regimens [43,44]. Brown et al. con-
cluded that odds of having osteoporosis was 1.6 times
higher if patients where PI-treated [45]. We suggest that
the interaction between PI and vitamin D metabolism
Role of vitamin D locally at the inflammation site – example  based on Mtb infection Figure 1
Role of vitamin D locally at the inflammation site – 
example based on Mtb infection. 1,25-(OH)2D, the 
active form of vitamin D produced by macrophage-CYP27B1 
at the inflammation site, has many local actions leading to a 
negative feedback loop avoiding macrophage overstimulation. 
1,25-(OH)2D reduces T helper (Th1) lymphocyte-mediated 
macrophage activation, (a) by activating regulatory T-cells 
(Treg) which inhibit the activation of Th1 lymphocytes by 
antigen-presenting cells (APC) [36], (b) by directly inhibiting 
activation of Th1 lymphocytes and thus their interferon-γ 
(IFN-γ) production, and (c) by preventing antigen presenta-
tion by APC to Th1 lymphocytes [34]. 1,25-(OH)2D acts also 
directly on macrophages (d) by reducing expression of Toll-
like receptor (TLR) to Mycobacterium tuberculosis (Mtb) [34], 
and (e) by inducing intracellular Mtb destruction via the 
cathelicidin-mediated system. If macrophages are overstimu-
lated, high local level of 1,25-(OH)2D could lead to systemic 
spill over and thus hypercalcemia, as has been described in 
Mtb-IRIS [39], since no systemic negative feedback by the 
parathyroid axis exists on macrophage-1,25-hydroxylase 
(CYP27B1) [15].
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Vitamin D production in macrophages and PI interaction Figure 2
Vitamin D production in macrophages and PI inter-
action. The 25-hydrolylase CYP3A4 converts vitamin D into 
25-(OH)D, its inactive form. To be active, the circulating 25-
(OH)D is 1-α-hydroxylated by the renal or the extrarenal 
P450 cytochrome (CYP27B1) into 1,25-(OH)2D. Both 25-
(OH)D and 1,25-(OH)2D can also be catabolized by 24-
hydroxylation (CYP24A1) into 24,25-(OH)2D and 1α,24,25-
(OH)2D respectively [33]. Activated macrophages possess 
both CYP27B1 and CYP24A1 and are able to produce 1,25-
(OH)2D locally at the site of inflammation. Protease inhibi-
tors (PI) inhibit the function of the hepatic-CYP3A4 and the 
macrophage-CYP27B1 which are critical for active vitamin D 
synthesis, and exert a milder inhibition on the activity of the 
24-hydroxylase (arrows). The net effect is a reduced produc-
tion of 1,25-(OH)2D [22] that could influence immunity.
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could result in an increased risk of IRIS in patients treated
with a PI-based regimen [29].
Testing the hypothesis
Our hypothesis could be explored by a case-control study
to assess the prevalence of vitamin D deficiency in HIV
infected patients on HAART who develop and do not
develop IRIS. In cohort studies of patients initiated on
HAART, the incidence of IRIS should be compared in
patients with low, normal and high baseline vitamin D
levels.
Moreover, polymorphisms of the VDR, the VDBP and the
enzymes involved in vitamin D production should be
investigated. We also propose to perform functional test-
ing of vitamin D enzymes to find out if an increase of the
vitamin D catabolism or a decrease of its production
could contribute to low 1,25-(OH)2D concentrations at
the site of inflammation, possibly leading to IRIS. Finally
remains the issue whether the levels of vitamin D that are
currently accepted as 'sufficient' for bone health apply to
'global health' and in particular anti-bacterial and anti-
inflammatory properties of vitamin D [46].
Implication of the hypothesis
There is an inter-relationship between vitamin D metabo-
lism, HAART therapy and immunity. Impaired vitamin D
metabolism in macrophages, whether caused by vitamin
D deficiency or by HAART therapy, might be a determi-
nant of IRIS in HIV-positive individuals. The potential
role of vitamin D status in the pathogenesis of IRIS should
be investigated. Indeed, if the role of vitamin D in IRIS is
confirmed, vitamin D supplementation could be a cheap
and safe way to prevent IRIS.
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